Population pharmacokinetics of liposomal daunorubicin in children

Br J Clin Pharmacol. 2003 Oct;56(4):370-7. doi: 10.1046/j.1365-2125.2003.01886.x.


Aims: To investigate the population pharmacokinetics of daunorubicin in children after administration of liposomal daunorubicin (Daunoxome).

Methods: Plasma samples from 19 children with relapsed acute myeloic leukaemia and five children with other malignancies were collected. Daunoxome was administered as a 1- to 2.5 h infusion with doses ranging from 30 to 60 mg m(-2). Overall, 214 samples were analysed for daunorubicin using capillary electrophoresis, and population pharmacokinetic modelling was performed using NONMEM.

Results: The data were best described by a one compartment model. Inclusion of interoccasion variability in the model (16.7% for clearance) improved strongly the precision of the estimates. The inclusion of body surface area or height as a covariate decreased interindividual variability. However, the best fit was obtained using the absolute dose, and when weight was included as a covariate for clearance (CL) and volume of distribution (V ). The final parameter estimates were: CL 6.41 ml h(-1) kg(-1) +/- 0.5 51% and V 65.4 ml kg(-1) +/- 0.5 27% (population mean +/- 0.5 interindividual variability). The area under the curve at a dose of 60 mg m(-2) was 231 mg l (-1)h.

Conclusions: In comparison with free daunorubicin, Daunoxome shows a low volume of distribution, a lower clearance and a lower interindividual variability in these parameters. This might be advantageous in reducing the variability in exposure to the drug.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / blood
  • Antibiotics, Antineoplastic / pharmacokinetics*
  • Child
  • Child, Preschool
  • Daunorubicin / administration & dosage
  • Daunorubicin / blood
  • Daunorubicin / pharmacokinetics*
  • Drug Carriers
  • Humans
  • Infant
  • Infusions, Intravenous
  • Leukemia, Myeloid / drug therapy
  • Liposomes
  • Neoplasms / drug therapy
  • Recurrence


  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Liposomes
  • Daunorubicin